Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands |
12 Months Ended |
Dec. 31, 2021 |
Dec. 31, 2020 |
| Income Statement [Abstract] |
|
|
| Collaboration revenue |
$ 1,319
|
$ 430
|
| Operating expenses: |
|
|
| Research and development |
80,325
|
57,715
|
| General and administrative |
21,728
|
11,246
|
| Total operating expenses |
102,053
|
68,961
|
| Loss from operations |
(100,734)
|
(68,531)
|
| Other income (expense): |
|
|
| Interest expense |
(1,906)
|
(979)
|
| Interest income and other income (expense), net |
2,553
|
1,001
|
| Change in fair value of preferred stock warrant liability |
0
|
(69)
|
| Loss on debt extinguishment |
(1,233)
|
(222)
|
| Total other expense, net |
(586)
|
(269)
|
| Net loss |
$ (101,320)
|
$ (68,800)
|
| Net loss per share attributable to common stockholders—basic (in dollars per share) |
$ (2.73)
|
$ (6.23)
|
| Net loss per share attributable to common stockholders—diluted (in dollars per share) |
$ (2.73)
|
$ (6.23)
|
| Weighted average common shares outstanding—basic (in shares) |
37,171,147
|
11,046,802
|
| Weighted average common shares outstanding—diluted (in shares) |
37,171,147
|
11,046,802
|
| Comprehensive loss: |
|
|
| Net loss |
$ (101,320)
|
$ (68,800)
|
| Other comprehensive loss: |
|
|
| Unrealized losses on marketable securities |
(3)
|
(7)
|
| Total other comprehensive loss |
(3)
|
(7)
|
| Total comprehensive loss |
$ (101,323)
|
$ (68,807)
|